Advances in Zika virus vaccines and therapeutics: A systematic review

IF 17.7 1区化学 Q1 CHEMISTRY, MULTIDISCIPLINARY Accounts of Chemical Research Pub Date : 2024-03-01 DOI:10.4103/apjtm.apjtm_680_23

Shiza Malik, Khalid Muhammad, Omar Ahsan, Muhammad Tahir Khan, Ranjit Sah, Yasir Waheed

{"title":"Advances in Zika virus vaccines and therapeutics: A systematic review","authors":"Shiza Malik, Khalid Muhammad, Omar Ahsan, Muhammad Tahir Khan, Ranjit Sah, Yasir Waheed","doi":"10.4103/apjtm.apjtm_680_23","DOIUrl":null,"url":null,"abstract":"Zika virus (ZIKV) is the causative agent of a viral infection that causes neurological complications in newborns and adults worldwide. Its wide transmission route and alarming spread rates are of great concern to the scientific community. Numerous trials have been conducted to develop treatment options for ZIKV infection. This review highlights the latest developments in the fields of vaccinology and pharmaceuticals developments for ZIKV infection. A systematic and comprehensive approach was used to gather relevant and up-to-date data so that inferences could be made about the gaps in therapeutic development. The results indicate that several therapeutic interventions are being tested against ZIKV infection, such as DNA vaccines, subunit vaccines, live-attenuated vaccines, virus-vector-based vaccines, inactivated vaccines, virus-like particles, and mRNA-based vaccines. In addition, approved anti-ZIKV drugs that can reduce the global burden are discussed. Although many vaccine candidates for ZIKV are at different stages of development, none of them have received Food and Drug Authority approval for use up to now. The issue of side effects associated with these drugs in vulnerable newborns and pregnant women is a major obstacle in the therapeutic pathway.","PeriodicalId":1,"journal":{"name":"Accounts of Chemical Research","volume":"23 3","pages":""},"PeriodicalIF":17.7000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Accounts of Chemical Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4103/apjtm.apjtm_680_23","RegionNum":1,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}

引用次数: 0

Abstract

Zika virus (ZIKV) is the causative agent of a viral infection that causes neurological complications in newborns and adults worldwide. Its wide transmission route and alarming spread rates are of great concern to the scientific community. Numerous trials have been conducted to develop treatment options for ZIKV infection. This review highlights the latest developments in the fields of vaccinology and pharmaceuticals developments for ZIKV infection. A systematic and comprehensive approach was used to gather relevant and up-to-date data so that inferences could be made about the gaps in therapeutic development. The results indicate that several therapeutic interventions are being tested against ZIKV infection, such as DNA vaccines, subunit vaccines, live-attenuated vaccines, virus-vector-based vaccines, inactivated vaccines, virus-like particles, and mRNA-based vaccines. In addition, approved anti-ZIKV drugs that can reduce the global burden are discussed. Although many vaccine candidates for ZIKV are at different stages of development, none of them have received Food and Drug Authority approval for use up to now. The issue of side effects associated with these drugs in vulnerable newborns and pregnant women is a major obstacle in the therapeutic pathway.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

寨卡病毒疫苗和疗法的进展：系统综述

寨卡病毒（ZIKV）是一种病毒感染的病原体，可导致全球新生儿和成人出现神经系统并发症。其广泛的传播途径和惊人的传播速度引起了科学界的极大关注。为了开发治疗 ZIKV 感染的方案，已经进行了大量试验。本综述重点介绍了针对 ZIKV 感染的疫苗和药物研发领域的最新进展。我们采用了一种系统而全面的方法来收集相关的最新数据，以便对治疗开发方面的差距做出推断。研究结果表明，目前正在测试几种针对 ZIKV 感染的治疗干预措施，如 DNA 疫苗、亚单位疫苗、减毒活疫苗、病毒载体疫苗、灭活疫苗、病毒样颗粒和基于 mRNA 的疫苗。此外，还讨论了可减轻全球负担的已获批准的抗 ZIKV 药物。尽管许多 ZIKV 候选疫苗正处于不同的开发阶段，但迄今为止还没有一种疫苗获得食品药品管理局的批准。这些药物对易感新生儿和孕妇的副作用问题是治疗道路上的一大障碍。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Accounts of Chemical Research 化学-化学综合

CiteScore

31.40

自引率

1.10%

发文量

312

审稿时长

2 months

期刊介绍： Accounts of Chemical Research presents short, concise and critical articles offering easy-to-read overviews of basic research and applications in all areas of chemistry and biochemistry. These short reviews focus on research from the author’s own laboratory and are designed to teach the reader about a research project. In addition, Accounts of Chemical Research publishes commentaries that give an informed opinion on a current research problem. Special Issues online are devoted to a single topic of unusual activity and significance. Accounts of Chemical Research replaces the traditional article abstract with an article "Conspectus." These entries synopsize the research affording the reader a closer look at the content and significance of an article. Through this provision of a more detailed description of the article contents, the Conspectus enhances the article's discoverability by search engines and the exposure for the research.